Informational only. Not medical advice.INFORMATIONAL PLATFORM ONLY — NOT MEDICAL ADVICE, DIAGNOSIS, OR TREATMENT
Informational only. Not medical advice.INFORMATIONAL PLATFORM ONLY — NOT MEDICAL ADVICE, DIAGNOSIS, OR TREATMENT
Head-to-head comparison of Coluracetam and Piracetam — mechanism, side effects, legal status, and pricing.
Coluracetam is a non-peptide small-molecule racetam-family nootropic (pyrrolidinone-substituted tetrahydrofuroquinoline) that enhances high-affinity choline uptake (HACU), the rate-limiting step in acetylcholine synthesis. Originally developed by Mitsubishi Tanabe Pharma as MKC-231 for Alzheimer's disease and later by BrainCells Inc. as BCI-540 for major depressive disorder, it is not FDA-approved for any indication and remains inactive in U.S. regulatory development. Sold only as an unregulated research chemical/nootropic powder with no validated human dose or safety profile.
Piracetam is a non-peptide pyrrolidinone-derivative racetam, the prototypical member of the nootropic racetam class. It is approved in the EU/UK exclusively for adult cortical myoclonus as adjunctive therapy (marketed as Nootropil), but has NO FDA approval in any form in the United States. The FDA has rejected its New Dietary Ingredient notification and issued warning letters to US vendors marketing it as a supplement. Piracetam itself is not WADA-prohibited, though its derivative phenylpiracetam is a banned stimulant.
Coluracetam
Piracetam
Category
Legal Status
Mechanism
Side Effects
COA-verified vendors · trust score ≥70 required · single-vial price — bulk/bundle deals may be lower
Coluracetam
Piracetam
No pricing data yet.
Check Piracetam prices →COA corpus from Disclosed Labs — independently tested batches only.
Coluracetam
2
COAs
99.7%
Avg purity
2
Labs
Piracetam
1
COAs
99.8%
Avg purity
1
Labs
No peer-reviewed or regulatory-posted human efficacy or safety data exist. One Phase 2 randomized, double-blind, placebo-controlled trial (NCT00621270) tested BCI-540 (80 mg once daily or three times daily vs. placebo) in 115 participants with major depressive disorder and concomitant anxiety (Jan 2008–Oct 2009); the trial is listed as Completed but has no results posted (hasResults=false, confirmed via ClinicalTrials.gov). In rodent models, oral coluracetam (1–10 mg/kg) significantly improved Morris water-maze learning deficits in AF64A-lesioned rats without tremor, salivation, or hypothermia, and reversed working-memory deficits and hippocampal acetylcholine depletion in AF64A-treated mice (Bessho et al. 1996, PMID 8740080; Murai et al. 1994, PMID 7710736). Coluracetam is not FDA-approved for any indication; U.S. development for Alzheimer's disease is listed as Inactive.
Key references
Piracetam is an approved prescription drug in the EU/UK for adult cortical myoclonus (adjunctive therapy) and has been studied off-label in multiple placebo-controlled human trials for age-related cognitive decline, post-stroke aphasia, post-ECT cognitive deficit, and post-CABG cognitive decline, with mixed results. A Cochrane systematic review (2001) concluded that available evidence does not support piracetam's use for dementia or cognitive impairment beyond a global-impression measure. In rodent models, piracetam reduced focal ischemia infarct volume by ~35.8%, improved neurological/locomotor outcomes and survival, attenuated oxidative stress and excitatory amino acid release in oxygen-glucose deprivation, and showed anticonvulsant and neuroprotective effects in PTZ-induced epilepsy.
Coluracetam and Piracetam are both in the Cognitive category and may have overlapping mechanisms. Researchers should review both profiles carefully, understand the mechanisms of action, and monitor the relevant biomarkers when combining compounds in the same class. As always, consult a licensed healthcare provider before making any decisions about combining research compounds.
This platform provides informational tools only, not medical advice. This comparison is for educational purposes only. Consult a licensed provider.
Contraindications
Lab Testing
Key references
Disclosed Labs